Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Return on Invested Capital (2020 - 2024)

C4 Therapeutics' Return on Invested Capital history spans 5 years, with the latest figure at 0.52% for Q4 2024.

  • For Q4 2024, Return on Invested Capital rose 9.0% year-over-year to 0.52%; the TTM value through Dec 2024 reached 0.52%, up 9.0%, while the annual FY2025 figure was 0.49%, 3.0% up from the prior year.
  • Return on Invested Capital reached 0.52% in Q4 2024 per CCCC's latest filing, down from 0.49% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.37% in Q3 2020 to a low of 0.89% in Q4 2020.
  • Average Return on Invested Capital over 5 years is 0.35%, with a median of 0.48% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: dropped -30bps in 2023, then increased 12bps in 2024.
  • A 5-year view of Return on Invested Capital shows it stood at 0.89% in 2020, then surged by 72bps to 0.25% in 2021, then dropped by -24bps to 0.31% in 2022, then tumbled by -96bps to 0.61% in 2023, then grew by 14bps to 0.52% in 2024.
  • Per Business Quant, the three most recent readings for CCCC's Return on Invested Capital are 0.52% (Q4 2024), 0.49% (Q3 2024), and 0.48% (Q2 2024).